FMI
KALV

F/M Investments’s KalVista Pharmaceuticals KALV Stock Holding History

F/M Investments’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.57M Sell
226,991
-9,699
-4% -$156K 0.3% 71
2025
Q4 		$3.82M Buy
236,690
+37,486
+19% +$496K 0.15% 172
2025
Q3 		$2.43M Buy
199,204
+16,942
+9% +$234K 0.09% 216
2025
Q2 		$2.06M Buy
182,262
+132,165
+264% +$1.62M 0.07% 238
2025
Q1 		$578K Buy
+50,097
New +$511K 0.02% 320

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

F/M Investments's KALV Position: Q1 2026 in Review

F/M Investments reduced its KalVista Pharmaceuticals (KALV) stake by 4.1% in Q1 2026, selling an estimated $156K and leaving 226,991 shares worth $4.57M. The position accounts for 0.3% of the portfolio, ranked #71.

F/M Investments first reported a position in KALV in Q1 2025 and has held it in 5 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • F/M Investments held 226,991 shares of KalVista Pharmaceuticals worth $4.57M as of Q1 2026.
  • F/M Investments sold 9,699 KalVista Pharmaceuticals shares in Q1 2026, an estimated $156K.
  • KalVista Pharmaceuticals made up 0.3% of F/M Investments's portfolio in Q1 2026, its #71 holding.
  • F/M Investments first reported a position in KalVista Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on F/M Investments's 13F filing for Q1 2026, filed 11 May 2026.